The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial.
Jeff Porter Sharman
Research Funding - Gilead Sciences
Steven E. Coutre
Research Funding - Gilead Sciences
Richard R. Furman
Research Funding - Gilead Sciences
Bruce D. Cheson
Research Funding - Gilead Sciences
John M. Pagel
Research Funding - Gilead Sciences
Peter Hillmen
Research Funding - Gilead Sciences
Jacqueline Claudia Barrientos
Research Funding - Gilead Sciences
Andrew David Zelenetz
Research Funding - Gilead Sciences
Thomas J. Kipps
Research Funding - Gilead Sciences
Ian Flinn
Research Funding - Gilead Sciences
Paolo Ghia
Research Funding - Gilead Sciences
Michael J. Hallek
Research Funding - Gilead Sciences
Bertrand Coiffier
Research Funding - Gilead Sciences
Susan Mary O'Brien
Research Funding - Gilead Sciences
Eugen Tausch
Research Funding - Gilead Sciences
Karl A Kreuzer
Research Funding - Gilead Sciences
Wendy Jiang
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Thomas Michael Jahn
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Mirella Lazarov
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Stephan Stilgenbauer
Research Funding - Gilead Sciences